ADICON Holdings Limited (Stock Code: 9860) has announced that, effective February 13, 2026, Mr. Wang Legang has been appointed as an Executive Director. He has served as the Chief Operating Officer and the General Manager of the Group since August 15, 2025, and will continue in these roles.

Mr. Wang, aged 45, brings extensive healthcare business management and digital transformation experience. His professional background includes positions at Qingdao Huanghai Pharmaceutical, Pfizer (China) Investment, Merck (China) Investment, Medlinker, Cowell Health, and Jointown Pharmaceutical Group. He graduated from Harbin Medical University with a bachelor’s degree in clinical pharmacy in June 2004 and later completed EMBA courses at Ocean University of China in November 2014.

Under a three-year service agreement, Mr. Wang’s Executive Directorship is subject to retirement by rotation and re-election in accordance with the Company’s articles of association. He does not receive a director’s fee for this position. According to the listing rules, he has confirmed that he holds no directorships in other listed companies over the past three years, has no relationships with directors or shareholders of ADICON Holdings, and does not hold any shares of the Company or its associated corporations.

In addition, Mr. Wang has been appointed as a member of the Company’s Strategy Committee with effect from February 13, 2026.